New Studies to Detect Early-Stage Mesothelioma

April 19, 2011 - PRLog -- Mesothelioma is a type of cancer which is aggressive and deadly compared to other forms of cancer. Exposure in asbestosis the main cause of the disease and it detect only in its advanced stages. Particularly, the treatment options are of limited effectiveness.

Last April 4 the study was presented at the American Association for Cancer Research’s 102nd annual meeting. The discovery could be a game changer according to Mesothelioma lawyers and experts.

For more details and a preview look here:
http://www.knowthecancer.com/new-studies-to-detect-early-stage-mesothelioma

NYU Langone Medical Center the new researchers that giving victims of asbestos exposure a valuable tool and hope. The researchers develop a novel protein test which is effective at detecting early-stage mesothelioma. The NYU test identifies proteins secreted from cancerous tumors caused by asbestos exposure.

According to Dr. Harvey I. Pass, director of the Division of Thoracic Surgery and Thoracic Oncology at NYU Langone Medical Center and the NYU Cancer Institute, and also the leader of researcher, “The only patients that seem to benefit from therapy in mesothelioma are those that are found in Stage 1, and this is only 10 to 15 percent of patients.”

“Moreover, when found early, the magnitude of the operation necessary to reduce the burden of disease may be less, making the patient better able to cope if the disease recurs and the patient needs more aggressive therapy,” Dr. Harvey I. Pass said.

Mesothelioma disease can avoid by means of the manufacturer need the asbestos to have properly handled or followed safety precautions; it makes the asbestos exposure prevented.
New Studies to Detect Early-Stage Mesothelioma

According to the mesothelioma lawyers, they obtain compensation and accountability for those harmed by the negligent asbestos-related actions of others. This is not only for the victim it is also to their families.

15 to 19 cases of stage 1 or stage 2 in a blind test performed under the sponsorship of the National Cancer Institute’s Early Detection Research Network Biomarker Discovery Lab according to NYU researchers. They test a 170 blood sample about 90 diagnosed of cancer and 80 were previously exposed to asbestos.

Multiplex SOMAmer Assay by SomaLogic Inc. is a leveraging a technology that measures 19 protein biomarkers for mesothelioma and developed by NYU team. These enable to find and quantify the small amount of these proteins secreted by tumor cells, and to detect the early-stage mesothelioma.

“Refining the test and validating the results in other patient blood samples,” Pass said.

For more details and a preview look here:
http://www.knowthecancer.com/new-studies-to-detect-early-...


# # #

Know The Cancer is a topic to gives facts causes cancers. This may elaborate different types of cancers; it gives details throughout the whole system either for men or women: http://www.knowthecancer.com